NCT03297606
|
Phase II |
Bosutinib
Palbociclib
Vismodegib
Nivolumab + Ipilimumab
Vemurafenib + Cobimetinib
Temsirolimus
Olaparib
Erlotinib
Crizotinib
Sunitinib
Afatinib
Dasatinib
Pertuzumab + Trastuzumab
Axitinib
|
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) |
Recruiting |
NCT02693535
|
Phase II |
Vemurafenib + Cobimetinib
Regorafenib
Vismodegib
Bosutinib
Palbociclib
Cetuximab
Axitinib
Pembrolizumab
Temsirolimus
Dasatinib
Pertuzumab + Trastuzumab
Crizotinib
Sunitinib
Olaparib
Erlotinib
|
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer |
Recruiting |
NCT01831726
|
Phase II |
Dovitinib
|
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib |
Completed |